Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Lumvoa Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Lumvoa (veligrotug-vvze) Continuation Therapy

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation of Lumvoa (veligrotug-vvze) for members with thyroid eye disease under the MassHealth UPPL. It applies to medical-benefit coverage and notes that Lumvoa is also available through the pharmacy benefit.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyLumvoa (veligrotug-vvze) Continuation Therapy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJanuary 4, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization for Lumvoa and document inadequate response, adverse reaction, or contraindication to glucocorticoids.
    SourceLink
    POLICY UPDATE CHANGES

    Lumvoa injection was added to both the pharmacy and medical benefits with a prior authorization requirement.

    The policy added a glucocorticoid step-through requirement and requires confirmation of no historical treatment with Tepezza.

    5 infusionsMaximum infusions in one course
    4 monthsMaximum duration of one course
    1 courseLifetime course limitation
    90 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    New-plan documentation period
    18+Minimum age

    Lumvoa Coverage Criteria

    New-to-plan continuation

    For members new to the plan, coverage may be considered when current treatment with the requested drug is documented.

    New-to-plan documentation: The member's coverage effective date is less than or equal to 90 days, and medical records document current treatment with Lumvoa. Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify as documentation of current treatment.Coverage effective date ≤ 90 days

    This pathway is an alternative to the standard authorization criteria.

    Standard Lumvoa authorization

    Authorization may be granted when all of the following criteria are met.

    Standard authorization criteria

    • The member has a diagnosis of thyroid eye disease.
    • The member is 18 years of age or older.Age ≥ 18 years
    • The prescriber is an endocrinologist or ophthalmologist, or consultation notes from an endocrinologist or ophthalmologist are provided.
    • The member has an inadequate response, an adverse reaction, or a contraindication to glucocorticoids.
    • The member has no history of treatment with Tepezza.
    • The requested dosing is appropriate.

    Continuation therapy and repeat courses

    Reauthorization by a physician may be granted for members who have not completed 4 months or 5 infusions of treatment. Additional courses are evaluated case by case for medical necessity.

    Continuation and repeat-course review: For reauthorization, the member has not completed 4 months or 5 infusions of treatment. Any additional course beyond the initial course must be supported by case-by-case medical-necessity review considering disease severity, response to prior courses, adherence to prior courses, failed alternative trials, and other relevant factors.Maximum 5 infusions (4 months) for one course of therapy per lifetime

    Repeat treatment beyond the initial course is not automatically authorized.

    For members whose coverage effective date is 90 days or less, medical records must document that the member is currently receiving Lumvoa. Treatment obtained as samples or through a manufacturer’s patient assistance program does not qualify as current-treatment documentation.

    Coverage beyond 5 infusions or 4 months, or for more than one course per lifetime, is limited. Any additional treatment requires a case-by-case medical-necessity review.

    Authorization and Documentation Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Lumvoa (veligrotug-vvze) under the MassHealth UPPL. The drug is available through both the medical and pharmacy benefits; submit the request under the applicable benefit.

    • MassHealth UPPL requirement applies.
    • Lumvoa is available on both the medical benefit and pharmacy benefit.
    • Medical benefit: 833-895-2611; fax 888-656-6671.
    • Pharmacy benefit: 800-711-4555; fax 844-403-1029.
    Documentation Required

    Clinical Authorization Criteria

    Authorization may be granted when the member meets all clinical requirements for Lumvoa treatment for thyroid eye disease.

    • Diagnosis of thyroid eye disease.

    Drug and Indication Background

    Lumvoa (veligrotug-vvze) is indicated for the treatment of thyroid eye disease regardless of disease activity or duration. The policy addresses authorization and continuation of therapy, with treatment limited to one course of up to 5 infusions over 4 months; additional courses require individualized medical-necessity review.

    Continuation and Reauthorization

    Lumvoa continuation and reauthorization

    Physician reauthorization is required before completion of the current treatment course; repeat courses require individualized medical-necessity review.

    Lumvoa continuation and reauthorization: The member has not completed 4 months or 5 infusions of treatment for reauthorization. Additional courses beyond the initial course are evaluated case by case, considering severity of disease, response to prior courses of therapy, adherence to prior courses, failed alternative trials, and other relevant factors.Less than 4 months or fewer than 5 infusions; maximum 5 infusions (4 months) for one course per lifetime

    The policy does not provide automatic approval for repeat courses.

    Required Glucocorticoid Step-Through

    StepPrior therapy requirementLumvoa authorization
    1Member must have an inadequate response, adverse reaction, or contraindication to glucocorticoids.Required before authorization

    Course and Lifetime Limits

    Quantity limits
    DrugLumvoa
    Maximum infusions5 infusions
    Maximum duration4 months
    Lifetime limitOne course of therapy per lifetime
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyLumvoa (veligrotug-vvze) Continuation Therapy
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJanuary 4, 2027
    Next Review DateN/A
    Key ActionSubmit prior authorization for Lumvoa and document inadequate response, adverse reaction, or contraindication to glucocorticoids.
    SourceLink
    On This Page
    Lumvoa Coverage CriteriaAuthorization and Documentation ActionsDrug and Indication BackgroundContinuation and ReauthorizationRequired Glucocorticoid Step-ThroughCourse and Lifetime Limits
  1. Member is 18 years of age or older.
  2. Prescriber is an endocrinologist or ophthalmologist, or consult notes from one of these specialists are submitted.
  3. Inadequate response, adverse reaction, or contraindication to glucocorticoids.
  4. No history of treatment with Tepezza.
  5. Appropriate dosing.
  6. Step Therapy

    Glucocorticoid Step-Through Required

    Before Lumvoa can be authorized, document an inadequate response, adverse reaction, or contraindication to glucocorticoids.

    • A qualifying glucocorticoid step-through is required.
    • Document the applicable inadequate response, adverse reaction, or contraindication.
    Documentation Required

    Current Treatment Records for New-Plan Members

    For a member new to the plan, submit medical records showing that the member is currently receiving treatment with the requested drug when the coverage effective date is 90 days or less before the request.

    • Records must document current treatment with Lumvoa.
    • Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.
    Documentation Required

    Clinical Authorization Documentation

    Include documentation supporting the member's diagnosis, age, specialist involvement, prior glucocorticoid experience, treatment history, and requested dosing.

    • Thyroid eye disease diagnosis.
    • Member age of at least 18 years.
    • Endocrinologist or ophthalmologist as prescriber, or specialist consultation notes.
    • Inadequate response, adverse reaction, or contraindication to glucocorticoids.
    • No prior Tepezza treatment.
    • Appropriate Lumvoa dosing.
    Documentation Required

    Reauthorization and Repeat-Course Documentation

    Reauthorization may be granted by the physician when the member has not completed the initial 4-month course of 5 infusions. Additional courses beyond the initial course require case-by-case review for medical necessity.

    • For repeat courses, document disease severity, response to prior courses, adherence to prior courses, failed alternative trials, and other factors supporting medical necessity.
    Denial Risk

    Failure to Meet Authorization Criteria

    Requests may be denied when the applicable authorization criteria are not met. The submission must support the required disease, age, specialist, treatment-history, step-through, and dosing requirements.

    • Denial risk applies when the member does not have thyroid eye disease or is younger than 18.
    • Denial risk applies when the required endocrinology or ophthalmology prescriber or consultation documentation is absent.
    • Denial risk applies when glucocorticoid step-through is not documented, the member has a history of Tepezza treatment, or dosing is not appropriate.
    Billing Rule

    Lifetime Course and Duration Limit

    Approvals are limited to one course per lifetime, with a maximum of 5 infusions over 4 months.

    • Maximum: 5 infusions.
    • Maximum duration: 4 months.
    • Additional treatment beyond the lifetime course limit is not approved under the standard authorization.
    Denial Risk

    Insufficient New-Plan Treatment Documentation

    New-plan treatment records must demonstrate qualifying current treatment with Lumvoa. Records based only on samples or manufacturer assistance treatment are insufficient.

    • Applies when the member's coverage effective date is 90 days or less before the request.
    • Submit medical records documenting current treatment with the requested drug.
    • Exclude treatment obtained as samples or through a manufacturer's patient assistance program.